MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more
MapLight Therapeutics, Inc. Common Stock (MPLT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.136x
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has a cash flow conversion efficiency ratio of -0.136x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.79 Million) by net assets ($233.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MapLight Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MapLight Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Foran Mining Corporation
OTCQX:FMCXF
|
0.000x |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
0.079x |
|
Alliance Material Co., Ltd.
TWO:3595
|
0.027x |
|
Northern Data AG
PINK:NDTAF
|
-0.021x |
|
Bonesupport Holding AB
ST:BONEX
|
0.085x |
|
Wonik Holdings Co. Ltd
KQ:030530
|
0.029x |
|
REPT BATTERO Energy Co., Ltd.
F:L52
|
N/A |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
0.093x |
Annual Cash Flow Conversion Efficiency for MapLight Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of MapLight Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $115.19 Million | $-78.81 Million | -0.684x | +6.22% |
| 2023-12-31 | $71.28 Million | $-52.01 Million | -0.730x | +42.71% |
| 2022-12-31 | $20.87 Million | $-26.58 Million | -1.273x | -- |